BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 14595389)

  • 1. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption.
    Rabitsch W; Knöbl P; Prinz E; Keil F; Greinix H; Kalhs P; Worel N; Jansen M; Hörl WH; Derfler K
    Bone Marrow Transplant; 2003 Nov; 32(10):1015-9. PubMed ID: 14595389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
    Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
    Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of persisting isohaemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation.
    Rabitsch W; Knöbl P; Greinix H; Prinz E; Kalhs P; Hörl WH; Derfler K
    Nephrol Dial Transplant; 2003 Nov; 18(11):2405-8. PubMed ID: 14551374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation.
    Fang B; Song Y; Li N; Li J; Han Q; Zhao RC
    Ann Hematol; 2009 Mar; 88(3):261-6. PubMed ID: 18769919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
    Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
    Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation.
    Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
    Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
    Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pure red cell aplasia after allogeneic transplantation of ABO incompatible hematopoietic stem cells].
    Bullorsky E; Shanley C; Stemmelin G; Ceresetto J; Rabinovich O
    Medicina (B Aires); 2002; 62(6):575-7. PubMed ID: 12532694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
    Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
    Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
    Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
    Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors.
    Hirokawa M; Fukuda T; Ohashi K; Hidaka M; Ichinohe T; Iwato K; Kanamori H; Murata M; Sakura T; Imamura M; Adachi S; Suzuki R; Morishima Y; Sakamaki H;
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1026-32. PubMed ID: 23583828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ABO incompatibility and non myeloablative allogeneic stem cell transplantation].
    Malfuson JV; Hicheri Y; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Transfus Clin Biol; 2007 Aug; 14(3):327-33. PubMed ID: 17462938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
    Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia.
    Maschan AA; Skorobogatova EV; Balashov DN; Pashanov ED; Trakhtman PE; Schipitzina IP; Skvortsova YV; Rumiantzev AG
    Bone Marrow Transplant; 2002 Sep; 30(6):405-7. PubMed ID: 12235527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
    Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pure red cell aplasia following ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Fan H; Jing Y; Li HH; Lu XC; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):364-7. PubMed ID: 18426666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion.
    Verholen F; Stalder M; Helg C; Chalandon Y
    Eur J Haematol; 2004 Dec; 73(6):441-6. PubMed ID: 15522068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.